Liver Cancer
Copyright ©2005 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 21, 2005; 11(7): 948-953
Published online Feb 21, 2005. doi: 10.3748/wjg.v11.i7.948
Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma
Shun-Yuan Jiang, Jung-Mao Chou, Fur-Jiang Leu, Yu-Yen Hsu, Yu-Lung Shih, Jyh-Cherng Yu, Meei-Shyuan Lee, Rong-Yaun Shyu
Shun-Yuan Jiang, Yu-Yen Hsu, Department of Microbiology and Immunology, National Defense Medical Center, Taipei 114, Taiwan, China
Meei-Shyuan Lee, School of Public Health, National Defense Medical Center, Taipei 114, Taiwan, China
Rong-Yaun Shyu, Yu-Lung Shih, Department of Internal Medicine, Tri-Service General Hospital, Taipei 114, Taiwan, China
Jung-Mao Chou, Department of Pathology, Armed Forces Tsoying Hospital, Kaohsiung 833, Taiwan, China
Jyh-Cherng Yu, Department of Surgery, Tri-Service General Hospital, Taipei 114, Taiwan, China
Fur-Jiang Leu, Department of Pathology, Cardinal Tien Hospital, Taipei 231, Taiwan, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Rong-Yaun Shyu, Section of Gastroenterology, Tri-Service General Hospital, 325 Chengung Rd, Sec. 2, Taipei 114, Taiwan, China. ryshyu612@ndmctsgh.edu.tw
Telephone: +886-2-8792-4844 Fax: +886-2-8792-7242
Received: June 15, 2004
Revised: June 17, 2004
Accepted: July 17, 2004
Published online: February 21, 2005
Abstract

AIM: To analyze the expression of retinoic acid receptor responder 3 (RARRES3) protein in paraffin-embedded tissues of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), and the correlation of RARRES3 production with tumor differentiation.

METHODS: Expression of RARRES3 in tissues from 21 CC (10 well-, 7 moderately- and 4 poorly-differentiated) and 32 HCC was determined by immunohistochemistry.

RESULTS: Among 21 CC tissues, RARRES3 was detected in 8 (80%) of 10 well-differentiated tumors. Only 2 (18.2%) out of 11 tumors with moderate or poor differentiation showed positive RARRES3 expression. RARRES3 expression in well-differentiated CC was significantly higher than that in tumors with moderate or poor differentiation (Fisher exact test, P<0.01). Expression of RARRES3 was not different between early (I and II) and late (III and IV) stages of CC. Among 30 HCC tissues, 17 (56.7%) weakly expressed RARRES3 in HCC cells, and 25 (83.3%) normal tissues adjacent to HCC expressed the protein. RARRES3 expression was significantly decreased in HCC tissues compared to that in adjacent normal tissues (logistic regression analysis, OR = 0.27, 95% CI (0.11-0.62), P<0.01).

CONCLUSION: Expression of RARRES3 is positively correlated to well-differentiated CC, which supports the role of RARRES3 in malignant epithelial differentiation of the tumor. The decrease in RARRES3 expression in tissues of HCC and CC with moderate and poor differentiation suggests that altered RARRES3 expression may play a role in the carcinogenesis of the liver and biliary tract.

Keywords: Retinoic acid receptor responder 3, RARRES3, RIG1, TIG3, Hepatocellular carcinoma, Cholangiocarcinoma